Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
PRNewswire - November 4, 2004
Research and Markets (http://www.researchandmarkets.com/reports/c8520) has announced the addition of The Competitive Landscape of HIV: Define Your Situation to their offering
This competitive analysis is based on our recently conducted global survey of the present players in HIV drug development field, their HIV drug portfolio, established partnerships, and breaking news. The HIV competitive landscape is divided into 5 major clusters of companies, whereof some are interconnected and other stands alone. The different clusters possess unique characteristics. Find out key data on each cluster, such as type of business interaction (9 classes) included, R&D Focus, Number of Drugs in Development, Competitive Edge, and Financial Strength etc. The report also includes an extensive appendix where you find detailed information regarding every mentioned Business Interaction. The appendix covers topics such as: parties, country, type of business interaction, status, date, terms and a detailed description of the business interaction. This competitive analysis sheds light and increases understanding of alliances that future partners are involved in, so that you can minimize the risk that competitors can gain information about what you are planning to do. This report will help you to position yourself on the global arena, and get critical information important for any tactical or strategic decision regarding collaboration, alliance, M&A etc. Even standing alone requires the force full knowledge about the capability of competitors.
The contents of this report are as follows:
- Introduction
- The Growing HIV Market
- What to Expect From the HIV Pharmaceutical Companies
- The Competitive Landscape of HIV Alliances
- Companies Between Powerful Clusters- Are they of Strategic Value?
- Vertex's Role as a Linker Between HIV Clusters
- The HIV Cluster Analysis
- The Major Cluster in HIV R&D
- The Drug Discovery Cluster
- The Swedish HIV Cluster
- The Danish HIV Cluster
- The Cluster that was created in 2004
- The M&A cluster
- The Late Stage Collaboration Cluster
- Selected Company Profiles
- Conclusion
For more information visit http://www.researchandmarkets.com/reports/c8520
Laura Wood, Senior Manager
Research and Markets
press@researchandmarkets.com - Fax: +353 1 4100 980
SOURCE Research and Markets
Web Site: http://www.researchandmarkets.com/reports/c8520
041104
PR041110
Copyright © 2004 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .